Abstract
The in vitro activity of RP59500, a streptogramin antibiotic, against 146 clinical isolates of vancomycin-resistant gram-positive bacteria was examined. Five strains of the species Enterococcus casseliflavus and Enterococcus gallinarum, for which the MIC of vancomycin was 8 micrograms/ml, were also studied. Twenty-eight vancomycin-susceptible strains of Enterococcus faecalis and Enterococcus faecium were included for comparison. The drug was highly active against Leuconostoc spp., Lactobacillus spp., and Pediococcus spp. (MICs, < or = 2 micrograms/ml). RP59500 was more active against vancomycin-susceptible strains of E. faecium than E. faecalis (MICs for 90% of the strains [MIC90s], 1.0 versus 32 micrograms/ml). Vancomycin-resistant strains of E. faecalis were as resistant to RP59500 as vancomycin-susceptible strains (MIC90, 32 micrograms/ml), but some vancomycin-resistant E. faecium strains were relatively more resistant to the new agent (MIC90, 16; MIC range, 0.5 to 32 micrograms/ml) than were vancomycin-susceptible organisms of this species.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aldridge K. E., Schiro D. D., Varner L. M. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother. 1992 Apr;36(4):854–855. doi: 10.1128/aac.36.4.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Aumercier M., Bouhallab S., Capmau M. L., Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):9–14. doi: 10.1093/jac/30.suppl_a.9. [DOI] [PubMed] [Google Scholar]
- Barrière J. C., Bouanchaud D. H., Paris J. M., Rolin O., Harris N. V., Smith C. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):1–8. doi: 10.1093/jac/30.suppl_a.1. [DOI] [PubMed] [Google Scholar]
- Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother. 1990 Dec;34(12):2291–2296. doi: 10.1128/aac.34.12.2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Etienne S. D., Montay G., Le Liboux A., Frydman A., Garaud J. J. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):123–131. doi: 10.1093/jac/30.suppl_a.123. [DOI] [PubMed] [Google Scholar]
- Fass R. J. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1991 Mar;35(3):553–559. doi: 10.1128/aac.35.3.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maple P. A., Hamilton-Miller J. M., Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet. 1989 Mar 11;1(8637):537–540. doi: 10.1016/s0140-6736(89)90076-7. [DOI] [PubMed] [Google Scholar]
- Verbist L., Verhaegen J. Comparative in-vitro activity of RP 59500. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):39–44. doi: 10.1093/jac/30.suppl_a.39. [DOI] [PubMed] [Google Scholar]